(Page 3 of 5)
much as $2 million more if they meet certain operating milestones on schedule. The deal was preceded by a series of acquisitions for Accelrys, including the 2012 buyouts of Velquest and Aegis, and the 2013 acquisition of Vialis nine months ago. Accelrys specializes in software that helps organizations better manage their scientific R&D and innovation.
—Shares of Isis Pharmaceuticals (NASDAQ: ISIS) have been strengthening since the Carlsbad, CA-based RNA interference drug developer reported interim data from an ongoing midstage trial of its experimental heart drug. The company said its experimental drug ISIS-APOCIIIRx reduced significantly triglycerides in more than 75 percent of the patients tested. The drug is being tested in patients with very high to severely high triglycerides.
—Elcelyx Therapeutics, the San Diego diabetes specialist, said it has spun out a separate company called NaZura BioHealth, and provided NaZura with a $5 million credit line to advance development of Lovidia, an over-the-counter dietary supplement meant for weight management. Elcelyx CEO Alain Baron also will serve as CEO of NaZura, and the two companies will share the same board of directors. NaZura intends to … Next Page »